In yesterday’s Wall Street session, Ocugen Inc (NASDAQ:OCGN) shares traded at $1.64, down -7.87% from the previous session.
OCGN stock price is now 89.84% away from the 50-day moving average and 189.86% away from the 200-day moving average. The market capitalization of the company currently stands at $420.66M.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
With the price target maintained at $3.50, Chardan Capital Markets recently Upgraded its rating from Neutral to Buy for Ocugen Inc (NASDAQ: OCGN). On August 23, 2022, Mizuho recently initiated its ‘Buy’ rating on the stock quoting a target price of $5, while ‘ROTH Capital’ rates the stock as ‘Buy’
In other news, Zhang Junge, Director bought 200,278 shares of the company’s stock on Jun 14 ’23. The stock was bought for $99,999 at an average price of $0.50. Upon completion of the transaction, the Director now directly owns 1,077,182 shares in the company, valued at $1.77 million. A total of 2.20% of the company’s stock is owned by insiders.
During the past 12 months, Ocugen Inc has had a low of $0.34 and a high of $2.11. As of last week, the company has a debt-to-equity ratio of 0.11, a current ratio of 5.08, and a quick ratio of 5.08. The fifty day moving average price for OCGN is $0.8863 and a two-hundred day moving average price translates $0.5718 for the stock.
The latest earnings results from Ocugen Inc (NASDAQ: OCGN) was released for Sep, 2023.
Ocugen Inc(OCGN) Company Profile
Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on the developing gene therapies to cure blindness diseases. The company’s pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, such as retinitis pigmentosa and leber congenital amaurosis; OCU410 and OCU410ST for the treatment of dry age-related macular degeneration (AMD); and OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet AMD. It has a strategic partnership with CanSino Biologics Inc. for gene therapy co-development and manufacturing; and Bharat Biotech for the commercialization of COVAXIN in the United States market. The company is headquartered in Malvern, Pennsylvania.
